Trials leave Galapagos’ SIK programme looking under the weather
pharmaphorum
JULY 16, 2021
Galapagos has had to send its SIK inhibitor programme back to the drawing board after its lead compound GLPG3970 has failed two of three clinical trials, adding to a string of disappointments for the Belgian biotech. . The preclinical compounds are expected to move into the human testing stage next year.
Let's personalize your content